THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio

July 17, 2024
Celltrion's Remsima SC hits record share in Europe in Q1

Celltrion’s subcutaneous injection formulation of the autoimmune disease treatment infliximab, known as Remsima SC or Zymfentra, has secured a bigger footing in Europe, the Korean biosimilar giant said Wednesday. Citing the global pharmaceutical market research firm IQVIA, Celltrion said that Rem...
July 11, 2024
Samsung invests W72b in US fund for AI-driven biotech

Samsung C&T and its biotech subsidiaries Samsung Biologics and Samsung Bioepis, announced Thursday they would invest 72 billion won ($52 million) in a US fund focused on startups using AI-based new power drug development platform technologies. The investment will be made through the Samsung Life S...
June 27, 2024
SK Bioscience to acquire German contract manufacturer IDT Biologika for W339b

South Korean biotech firm SK Bioscience is to acquire the German CDMO-specializing company IDT Biologika at 339 billion won ($244 million) to further sharpen and diversify its pipeline for global markets. IDT Biologika is among the top 10 global vaccine contract manufacturers, with a corporate val...
June 27, 2024
SK Pharmteco in talks to sell Virginia plant to Novo Nordisk

SK Pharmteco, a contract development manufacturing organization affiliated with SK Group, is considering selling its manufacturing plant in Virginia to Danish pharmaceuticals company Novo Nordisk, according to industry sources Wednesday. The Petersburg, Virginia plant is an active pharmaceutical i...
June 20, 2024
Kolmar Korea unveils AI-powered hair loss tool

Kolmar Korea, a cosmetics original design manufacturer, said Thursday that the company has developed an artificial intelligence-based solution that can diagnose hair loss, using scalp biomarkers. The new solution can diagnose 16 types of androgenic hair loss, including nine male and seven female t...
June 20, 2024
Samsung Biologics launch coporate culture change initiative

Samsung Biologics has launched an initiative to improve its corporate culture aimed at transforming it into a top-tier biopharmaceutical company by 2030. On Thursday, Samsung Biologics held a declaration ceremony, under a slogan dubbed “Samsung Biologics Way,” and pledged that the company's mana...
June 19, 2024
Daewoong's botulinum toxin Nuceiva hits Spanish market

Daewoong Pharmaceutical, South Korea’s leading drug company, said Wednesday its botulinum toxin product Nabota has been launched in Spain, one of Europe's largest aesthetic toxin injectable markets. According to Daewoong Pharmaceutical, its US partner Evolus, which has the exclusive right to impo...
June 13, 2024
Celltrion's Stelara biosimilar receives approval in Korea

South Korean biosimilar giant Celltrion announced Thursday that Steqeyma, the company’s biosimilar referencing Stelara, has been approved by the Ministry of Food and Drug Safety. Stelara (ustekinumab) is Johnson & Johnson's blockbuster drug used to treat patients with plaque psoriasis. According ...
June 12, 2024
Evolus CEO vows to boost US sales of Daewoong Jeuveau

David Moatazedi, CEO of Evolus, the US company that sells Daewoong Pharmaceutical's botulinum toxin product Jeuveau, has pledged to boost its US sales to $700 million by 2028, the Korean pharmaceuticals company said Wednesday. “Jeuveau is the fastest growing neurotoxin in the US for the past thre...
June 07, 2024
Daewoong confirms safety, efficacy of diabetes drug Envlo for dogs

Daewoong Pharmaceutical’s research that confirmed its diabetes drug Envlo’s safety and efficacy in animals has been published in Veterinary Medicine and Science, a peer-reviewed, open-access journal for research in all areas of veterinary medicine, the company said Friday. Daewoong Pharmaceutica...
June 07, 2024
SK Biopharmaceuticals seeks to expand R&D with surging Xcopri sales

"Having key players who set new standards is crucial in the bio business. Germany, the UK and the US were able to develop vaccines within a year during the COVID-19 pandemic, largely due to the efforts of immigrant scientists based in those countries. Likewise, SK Biopharma will actively scout such...
June 07, 2024
[Bio USA] Cha Biotech's Matica Bio sets sights on CGT market growth

SAN DIEGO -- Matica Biotechnology, the US subsidiary of CHA Biotech, which operates CHA University's medical centers in South Korea and internationally, has announced endeavors for significant expansion of its cell and gene therapy (CGT) CDMO orders in particular, setting itself apart from most ant...
June 05, 2024
[Bio USA] Cha Biotech's Matica Bio sets sights on CGT market growth

Matica Biotechnology, the US subsidiary of CHA Biotech, which operates CHA University's medical centers in South Korea and internationally, has announced endeavors for significant expansion of its cell and gene therapy (CGT) CDMO orders in particular, setting itself apart from most antibody product...
June 04, 2024
[Bio USA] Samsung Biologics unveils new platform at Bio USA

Samsung Biologics anticipates that S-Tensify will enhance its contract development services by transitioning from traditional Fed-Batch culture methods to high-concentration culture methods with improved productivity. Additionally, Samsung Biologics also launched a rebranded service to boost more ...
June 02, 2024
Korean biotech firms seek to shine at Bio USA amid China’s boycott

A record number of South Korean pharmaceutical and biotech companies are joining this week’s Bio International Convention to showcase their latest innovations and boost client partnerships amid the absence of their Chinese rivals. The event, also known as Bio USA, will run Monday through Thursday...

1 2 3 4 5 6

EDITOR'S PICKS

Herald Corporation |CEO : Choi Jin-Young |Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |Title : The Investor |Date of registration : 2016.06.21 |Date of issue : 2016.06.21
Publisher. Editor : Choi Jin-Young |Chief Privacy Officer & Juvenile Protection Manager : Choi He-suk |T +82-2-727-0021 |E investor@heraldcorp.com

FAMILY SITE GO

Company Registration No. 104-81-06004 |Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |Business info |Gov’t registration No. Seoul 아04099